GLOBAL BLOOD THERAPEUTICS IN's ticker is GBT and the CUSIP is 37890U108. A total of 227 filers reported holding GLOBAL BLOOD THERAPEUTICS IN in Q1 2020. The put-call ratio across all filers is 1.04 and the average weighting 0.2%.
Links
Filings
- All filings
- Annual reports (10-K)
- Quarterly reports (10-Q)
- Insider transactions
- Shareholder votes
- Significant ownership
- Events
EDGAR links
External links
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2022 | $13,805,000 | +6.9% | 202,718 | -49.8% | 0.00% | 0.0% |
Q2 2022 | $12,911,000 | -79.5% | 404,162 | -77.8% | 0.00% | -83.3% |
Q1 2022 | $62,947,000 | +38.2% | 1,817,187 | +16.8% | 0.01% | +50.0% |
Q4 2021 | $45,553,000 | -1.2% | 1,556,316 | -14.0% | 0.00% | -20.0% |
Q3 2021 | $46,085,000 | -78.6% | 1,808,657 | -70.5% | 0.01% | -77.3% |
Q2 2021 | $214,863,000 | -15.0% | 6,135,446 | -1.1% | 0.02% | -21.4% |
Q1 2021 | $252,774,000 | -3.8% | 6,203,069 | +2.3% | 0.03% | -17.6% |
Q4 2020 | $262,729,000 | -14.7% | 6,066,227 | +8.6% | 0.03% | -19.0% |
Q3 2020 | $308,103,000 | -11.0% | 5,587,638 | +1.9% | 0.04% | -20.8% |
Q2 2020 | $346,158,000 | +27.1% | 5,483,250 | +2.9% | 0.05% | +8.2% |
Q1 2020 | $272,350,000 | -27.3% | 5,330,814 | +13.1% | 0.05% | -9.3% |
Q4 2019 | $374,635,000 | +117.1% | 4,712,986 | +32.5% | 0.05% | +107.7% |
Q3 2019 | $172,577,000 | +0.3% | 3,556,822 | +8.7% | 0.03% | 0.0% |
Q2 2019 | $172,069,000 | +12.9% | 3,271,277 | +13.6% | 0.03% | +8.3% |
Q1 2019 | $152,395,000 | +46.0% | 2,879,173 | +13.2% | 0.02% | +33.3% |
Q4 2018 | $104,397,000 | +89.7% | 2,543,161 | +75.6% | 0.02% | +100.0% |
Q3 2018 | $55,040,000 | +153.4% | 1,448,419 | +201.4% | 0.01% | +125.0% |
Q2 2018 | $21,721,000 | +20.3% | 480,534 | +28.5% | 0.00% | +33.3% |
Q1 2018 | $18,058,000 | +8.9% | 373,857 | -11.3% | 0.00% | 0.0% |
Q4 2017 | $16,579,000 | +2729.2% | 421,333 | +2132.6% | 0.00% | – |
Q3 2017 | $586,000 | +244.7% | 18,872 | +204.1% | 0.00% | – |
Q2 2017 | $170,000 | -35.4% | 6,205 | -13.1% | 0.00% | – |
Q1 2017 | $263,000 | +415.7% | 7,141 | +103.6% | 0.00% | – |
Q4 2016 | $51,000 | +200.0% | 3,508 | +385.9% | 0.00% | – |
Q3 2016 | $17,000 | -83.5% | 722 | -88.4% | 0.00% | – |
Q2 2016 | $103,000 | +635.7% | 6,219 | +625.7% | 0.00% | – |
Q1 2016 | $14,000 | +180.0% | 857 | +413.2% | 0.00% | – |
Q4 2015 | $5,000 | -89.6% | 167 | -85.2% | 0.00% | – |
Q3 2015 | $48,000 | – | 1,129 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Alerce Investment Management, L.P. | 356,270 | $24,262,000 | 23.36% |
Twin Securities, Inc. | 376,669 | $25,651,000 | 11.94% |
Paradigm Biocapital Advisors LP | 1,175,879 | $80,077,000 | 10.68% |
Chicago Capital Management, LLC | 246,246 | $16,769,000 | 9.12% |
HARVEST MANAGEMENT LLC | 141,500 | $9,636,000 | 7.78% |
Fernwood Investment Management, LLC | 174,724 | $11,899,000 | 5.02% |
ArchPoint Investors | 168,725 | $11,490,000 | 4.69% |
HAVENS ADVISORS LLC | 46,000 | $3,133,000 | 4.69% |
Perceptive Advisors | 2,322,247 | $158,145,000 | 4.59% |
Crabel Capital Management, LLC | 112,680 | $7,674,000 | 4.48% |